News >

Kumar Discusses Latest Developments in Myeloma

Angelica Welch
Published: Thursday, Aug 17, 2017

Shaji Kumar, MD

Shaji Kumar, MD
At the 2017 European Hematology Association (EHA) Annual Congress, Shaji Kumar, MD, presented research showing that patients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant (SCT) but remained on single-agent ixazomib (Ninlaro) maintenance fared as well as those who received SCT.

at EHA, Kumar, professor of Medicine, Mayo Clinic, discussed his ixazomib maintenance trial, the latest FDA activity in myeloma, and the potential of chimeric antigen receptor (CAR) T-cell therapy in the field.

OncLive:  Please provide an overview of your study of ixazomib, lenalidomide, and dexamethasone?

Kumar: The combination of a proteasome inhibitor and an immunomodulatory drug remains the current standard for the initial therapy of multiple myeloma. The combination of bortezomib (Velcade) and lenalidomide (Revlimid) has shown improved overall survival (OS) and has become the most commonly used treatment in the United States, and its use is increasing around the world. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication